Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)

This study has been withdrawn prior to enrollment.
(Minimal enrollment)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Oklahoma
ClinicalTrials.gov Identifier:
NCT01195428
First received: September 2, 2010
Last updated: January 6, 2014
Last verified: January 2014

September 2, 2010
January 6, 2014
October 2010
October 2011   (final data collection date for primary outcome measure)
Incidence of ARDS/ALI. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01195428 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome

Acute Lung Injury/Acute respiratory distress syndrome (ALI/ARDS) is a serious and frequently encountered entity in modern ICUs. Sepsis remains the most common cause of ALI/ARDS and carries the worst prognosis. The disease is characterized by an intense inflammatory process. This inflammation plays a major role in the development of gas exchange abnormalities seen in the course of the disease. Statins, primarily used as lipid-lowering agents, are now known to possess anti-inflammatory, antioxidant, antithrombogenic and vascular function-restoring actions. Therefore the investigators propose to determine if Simvastatin may be useful in decreasing the incidence of this deadly syndrome in critically ill patients.

Patients will be enrolled within 24 hours of ICU admission and randomized to 1 of 2 groups: Simvastatin or placebo. Patients' management will be entirely left up to the primary team, including the need for daily laboratory and imaging. In addition, there will be no restriction on the use of any medications, as deemed necessary by the primary care physician. The primary endpoint will be the incidence of ALI/ARDS. Secondary efficacy variables will be the number of days without organ or system failure, in addition to the change in IL-6, IL-8, and TNF- α. Treatment will continue until the primary endpoint is reached, the patient discharged from the ICU or the maximum duration of 2 weeks, whichever occurs first. Patients will continued to be followed for a total of 28 days, or until discharged from the hospital, whichever occurs first.

Patients randomized, in a ratio of 1:1 to either Simvastatin 40 mg PO once daily or placebo tablet once daily in a format identical to Simvastatin.

The mortality from ALI/ARDS remains significant. In the absence of effective therapy, prophylaxis in patients at risk is an important goal to achieve. Therefore, if Simvastatin is found to decrease the incidence of ALI/ARDS, it would be a significant advance in the management of this deadly and frequent syndrome.

We have set up a Data Safety Monitoring Board (DSMB) that will closely monitor the progress of the trial (DSMB Charter attached to this application). Any adverse event will be reported directly to the institutional review board (IRB) and DSMB. All adverse events will be reported in the annual review of the protocol.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Adult Respiratory Distress Syndrome
  • Acute Lung Injury
  • Drug: Simvastatin
    Simvastatin 40 mg daily
  • Drug: Placebo
    Placebo
  • Active Comparator: Simvastatin
    Simvastatin 40 mg daily.
    Intervention: Drug: Simvastatin
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults older than 18 years of age, admitted to the ICU with one or more of the following risk factors for ARDS/ALI:

    • Sepsis, defined as the presence of infection-related systemic inflammatory response syndrome (SIRS).

SIRS is defined as the presence of two or more of the following:

  • Temperature >38.5ºC or <35ºC
  • Heart rate >90 beats/min
  • Respiratory rate >20 breaths/min or PaCO2 <32 mmHg
  • WBC >12,000 cells/mm3, <4000 cells/mm3, or >10 percent immature (band) forms

    • Pneumonia, including community and health care associated pneumonias
    • Aspiration, defined as the witnessed inhalation of gastric contents
    • Acute pancreatitis
    • Bilateral lung contusion
    • Massive transfusion, defined as more than 15 units of red blood cells/24h
    • Multiple (>2) long-bone fractures

Exclusion Criteria:

  • Patients already on a statin
  • Current indication for statin therapy according to the National guidelines
  • NPO order
  • Active liver disease, defined as ALT or AST > 3 times the upper limits of normal
  • History of myopathy
  • History of uncontrolled seizure disorder
  • Pregnancy or breastfeeding
  • Immunosuppressive therapy, including prednisone at dose > 10 mg/day
  • Preexistent lung disease indicated by history or chest film
  • High risk for cardiogenic pulmonary edema (defined as the presence of ventricular fibrillation, acute myocardial infarction, congestive heart failure with EF < 40%)
  • High risk for neurogenic pulmonary edema (active CVA, or known increased intracranial pressure)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01195428
15377
Yes
University of Oklahoma
University of Oklahoma
Department of Veterans Affairs
Principal Investigator: Jean Keddissi, M.D. University of Oklahoma
Principal Investigator: Gary T. Kinasewitz, MD University of Oklahoma
University of Oklahoma
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP